Plain-English translation of NCT06406205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called voclosporin can help treat active lupus nephritis—a serious condition where lupus damages the kidneys. You would take this medication by mouth twice a day for 52 weeks, along with your standard treatments. The study will compare how well people do with the medication versus those receiving a placebo (inactive pill) to see if it can reduce the amount of protein leaking into your urine, which is a key sign of kidney damage.
Lupus nephritis is a severe form of lupus that damages the kidneys and can lead to kidney failure. While current treatments help some people, doctors are looking for better options to protect the kidneys and help more patients achieve remission. This trial is testing whether this medication could offer a more effective approach when combined with standard care.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic regularly over 52 weeks (one year). Half of participants will receive the new medication as three capsules taken by mouth twice daily, and half will receive a placebo (fake pill) that looks identical. Everyone also receives standard lupus kidney treatments. Throughout the study, researchers will check your urine protein levels, kidney function, and overall health to see how the treatment is working.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China